# Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction

> **NCT03274752** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 50 (actual)

## Conditions studied

- Cardiac Remodeling
- Myocardial Infarction

## Interventions

- **DRUG:** Paroxetine
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03274752
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-26
- **Primary completion:** 2021-01-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274752, "Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03274752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*